The campaign will include patient stories, education resources, and is being held in partnership with the Glaucoma Research Foundation. Bausch + Lomb announced the launch of the second annual Faces of ...

Abrysvo and Arexvy will now be required to come with labeling that includes a warning about a potential increased risk of Guillain-Barré Syndrome. The FDA announced that it has mandated updates to the ...

In the race to bolster pipelines and drive growth, biopharma manufacturers are reexamining traditional practices and reimagining market research protocols. Biopharma business development and licensing ...

Mary Kosinski joined the firm as global managing director for the sector, along with other leadership additions. Mary Kosinski is the new global managing director of health and life sciences at ...

Swoop announced its acquisition of MyHealthTeam, creator of one of the largest opted-in patient social networks in the US. The companies share a vision of making vetted information more available for ...

Deloitte’s US life sciences sector leader discusses the trends he believes will have the most impact in 2025. According to a new report from Deloitte, the life sciences industry will have a ...

Fast Track designation was based on results from a Phase II study, which demonstrated that VGT-309 was safe, well-tolerated, and enhanced tumor visualization in lung cancer patients. The FDA has ...

Both companies have produced AI-powered technology that improves data collection and analysis. As the pharma industry continues to embrace new technologies, it’s becoming increasingly clear that the ...

The future is bright with AI-powered innovations, but migration presents significant risks, including data loss, increased costs, and disruption to business operations. The life sciences industry is ...

John Hood, CEO, Endeavor BioMedicines discusses a potential timeline on availability of ENV-101 for patients with IPF and further validation of the treatment's safety profile. PE: Given the ...

Data from the Phase III trial program found that AXS-05 demonstrated statistically significant efficacy in treating Alzheimer disease agitation. Axsome Therapeutics announced the successful completion ...

While challenges remain, AI is accelerating the process by enabling researchers to identify and design new drug candidates more quickly and efficiently with applications in target discovery, structure ...